Peginterferon alfa-2b
- Generic Name
- Peginterferon alfa-2b
- Brand Names
- Pegintron, Sylatron
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 215647-85-1
- Unique Ingredient Identifier
- G8RGG88B68
- Background
Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting...
- Indication
Peginterferon alfa-2b is indicated for the treatment of HCV in combination with Ribavirin and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 . May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
...
- Associated Conditions
- Chronic Hepatitis C Virus (HCV) Infection, Melanoma
- Associated Therapies
- -
Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients
- Conditions
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2022-04-05
- Target Recruit Count
- 5000
- Registration Number
- NCT05182463
- Locations
- 🇨🇳
Department of Infectious Diseases, The Third Affliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2019-05-22
- Target Recruit Count
- 100
- Registration Number
- NCT03920605
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Optimized Treatment of Peginterferon Alfa 2a/2b in Anti-virus Treatment Naive Patients With HBV Related Liver Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2019-04-19
- Target Recruit Count
- 120
- Registration Number
- NCT03919565
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 473
- Registration Number
- NCT03181113
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Second Affiliated Hospital Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Southwest Hospital, Chongqing, Chongqing, China
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
- Conditions
- Interventions
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Aiwu Ruth He, MD
- Target Recruit Count
- 4
- Registration Number
- NCT02982720
- Locations
- 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection
- Conditions
- Interventions
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2016-11-25
- Target Recruit Count
- 100
- Registration Number
- NCT02973646
- Locations
- 🇨🇳
The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
New Strategy Study of Functional Cure of Chronic Hepatitis B
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2016-09-20
- Target Recruit Count
- 120
- Registration Number
- NCT02605252
- Locations
- 🇨🇳
The third affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Peginterferon and TIL Therapy for Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Inge Marie Svane
- Target Recruit Count
- 12
- Registration Number
- NCT02379195
- Locations
- 🇩🇰
Center for Cancer Immune Therapy, Dept. of Haematology/Oncology, Copenhagen, Herlev, Denmark
Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)
- Conditions
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT02204475
Treatment of Advanced Melanoma With MK-3475 and Peginterferon
- First Posted Date
- 2014-04-11
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Hassane M. Zarour, MD
- Target Recruit Count
- 43
- Registration Number
- NCT02112032
- Locations
- 🇺🇸
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.